@article{MansourArevaloAlKahtanietal.2014,
  author    = {Mansour, Ahmad M. and Arevalo, J. Fernando and Al Kahtani, Eman and Zegarra, Hernando and Abboud, Emad and Anand, Rajiv and Ahmadieh, Hamid and Sisk, Robert A. and Mirza, Salman and Tuncer, Samuray and Navea Tejerina, Amparo and Mataix, Jorge and Ascaso, Francisco J. and Pulido, Jose S. and Guthoff, Rainer and Goebel, Winfried and Roh, Young Jung and Banker, Alay S. and Gentile, Ronald C. and Alonso Martinez, Isabel and Morris, Rodney and Panday, Neeraj and Min, Park Jung and Merce, Emilie and Lai, Timothy Y. Y. and Massoud, Vicky and Ghazi, Nicola G.},
  title     = {Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma},
  series = {Journal of Ophtamology},
  journal   = {Journal of Ophtamology},
  number    = {210458},
  doi       = {10.1155/2014/210458},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-117923},
  pages     = {8},
  year      = {2014},
  abstract  = {We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n = 15; P = 0.001), 105.3 microns at 1 year (n = 10; P = 0.03), and 157.6 microns at 2 years (n = 7; P = 0.08). BCVA improved by 3.3 lines at 6 months after therapy (n = 26; P < 0.001), 2.8 lines (n = 20; P = 0.01) at 1 year, and 3.1 lines (n = 13; P = 0.049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.},
  language  = {en}
}
@article{SchroederMeyerterVehnFassnachtRiederleetal.2016,
  author    = {Schroeder, Katharina and Meyer-ter-Vehn, Tobias and Fassnacht-Riederle, Heidi and Guthoff, Rainer},
  title     = {Course of disease in multifocal choroiditis lacking sufficient immunosuppression: a case report},
  series = {Journal of Medical Case Reports},
  volume    = {10},
  journal   = {Journal of Medical Case Reports},
  number    = {298},
  doi       = {10.1186/s13256-016-1069-2},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-171317},
  year      = {2016},
  abstract  = {Background: Multifocal choroiditis with panuveitis is a rare disease. The educational merit of this case presentation results from the good documentation and the impressive ocular fundus pictures. Case presentation: We illustrate the 3-year course of disease in a 22-year-old myopic white woman with multifocal choroiditis with panuveitis and secondary choroidal neovascularization. The activity of the disease was evaluated clinically by optical coherence tomography and fluorescein angiography. Choroidal neovascularization was treated by intravitreal bevacizumab (2.5 mg/0.1 ml). Our patient lacked systemic therapy for the first 11 months because of noncompliance. Conclusions: The case is remarkable as the delayed onset of peripheral lesions and the additional existence of high myopia made diagnosis difficult. In addition, it demonstrates that full outbreak of disease with multiple central and peripheral fundus lesions and secondary choroidal neovascularization can develop without systemic treatment.},
  language  = {en}
}